Novel membrane-based targets - Therapeutic potential in gynecological cancers

Crit Rev Oncol Hematol. 2015 Mar;93(3):293-303. doi: 10.1016/j.critrevonc.2014.10.015. Epub 2014 Nov 18.

Abstract

Recent advances have been made in the molecular profiling of gynecological tumors. These discoveries have led to the development of targeted therapies that have the potential to disrupt molecular pathways involved in the oncogenesis or tumor progression. In this review, we highlight areas of recent progress in the field of membrane receptor inhibitors in gynecological malignancies and describe the biological rationale underlying the inhibition of these receptors. We will introduce drug immuno-conjugates, and give an update on the biological rationale and the clinical studies involving agents directed against EGFR, HER3, IGFR, MET, FGFR, NOTCH, and TRAIL. We also discuss the challenge facing these new therapies.

Keywords: Gynecological malignancies; Membrane receptor inhibitors; Targeted therapies.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials as Topic
  • Female
  • Genital Neoplasms, Female / drug therapy*
  • Genital Neoplasms, Female / metabolism*
  • Genital Neoplasms, Female / mortality
  • Humans
  • Immunoconjugates / pharmacology
  • Immunoconjugates / therapeutic use
  • Molecular Targeted Therapy*
  • Receptors, Cell Surface / antagonists & inhibitors*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Immunoconjugates
  • Receptors, Cell Surface